Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
April 11, 2019 10:00 ET
|
Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
April 11, 2019 09:00 ET
|
Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...
Travelan® FY19 1st Half Update and Geographic Expansion into North America
January 29, 2019 09:30 ET
|
Immuron Limited
Key Highlights: Immuron achieved 7% YoY growth in worldwide sales for the first half of FY19.In the US, Travelan® exhibited double-digit growth for this period, with sales 10% higher than observed...
Immuron Receives $1.19M R&D Tax Concession Refund
January 08, 2019 02:32 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO
November 19, 2018 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Immuron Limited, (IMC or the Company), (ASX: IMC; NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive...
NASH clinical trial presentation and continued revenue growth
November 09, 2018 06:00 ET
|
Immuron Limited
Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San FranciscoTravelan® on display at HealthEdAustralian Travelan® sales continue to...
US Department of Defense Reports Travelan Protects Against Shigella in Primates
September 05, 2018 10:00 ET
|
Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
July 25, 2018 10:00 ET
|
Immuron Limited
Key Highlights: Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17.US Travelan® sales continue to exceed...
Immuron Announces it has Received a European Patent Grant for NASH treatment
July 24, 2018 06:30 ET
|
Immuron Limited
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally...
US Department of Defense Research Collaboration Moves Forward
July 24, 2018 06:28 ET
|
Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...